The FDA, Social Media & Consumer Genomics: A Lot Not to “Like” | Genomics Law Report

Last week, the FDA published on its website a warning letter to AMARC Enterprises, Inc., a marketer of a dietary supplement known as Poly-MVA. The letter, issued by a regional compliance office and dating to this past December, is unremarkable in most respects, focusing on website copy, printed information packets, customer testimonials and other materials that appear, at least to the FDA, to represent claims made by AMARC that the Poly-MVA supplement is “intended for use in the cure, mitigation...
Flag this


There are currently no comments. Add a new comment!

Post a comment

You must be logged in to post comments. Login now

Posted by Mike Spear


I am the Communications Director for Genome Alberta and we manage this application. In my past life I was a journalist and manager with the CBC. You can find my genome posted at

0 people like this

Be the first to like this